GlassScriptPhysician profile
Robert A Restifo
NPI 1760483804
$11,861.76
in general payments reported to CMS, 2019-2025
36 companies · $4,298 in 2025
The $4,298 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $842 · 2021: $863 · 2022: $1,230 · 2023: $1,780 · 2024: $1,618 · 2025: $4,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,246 · Education: $1,633 · Travel and Lodging: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,246.00 |
| Education | $1,633.00 |
| Travel and Lodging | $816.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,418.62 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Intuitive Surgical, INC. | $2,333.67 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,477.33 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,076.31 | 2019-2025 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Mylan Specialty L.P. | $509.50 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $445.47 | 2019-2025 | Dupixent |
| Genzyme Corporation | $409.27 | 2019-2025 | |
| Amgen INC. | $252.89 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $234.54 | 2020-2025 | Prolastin-C Liquid |
| Philips North America LLC | $216.79 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Insmed, INC. | $155.04 | 2019-2025 | Arikayce |
| Optinose US, INC. | $124.17 | 2019-2024 | |
| Pulmonx Corporation | $100.71 | 2020-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Verona Pharma, INC. | $91.43 | 2025 | Ohtuvayre |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $91.42 | 2025 | Yupelri |
| Genentech USA, INC. | $85.51 | 2019-2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $82.63 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $81.59 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $80.16 | 2019-2024 | Zerbaxa, Dificid |
| Octapharma USA, INC. | $78.73 | 2020-2022 | |
| Baxter Healthcare | $68.28 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Incyte Corporation | $62.48 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.62 | 2020-2024 | Aralast |
| Tempus Ai, INC | $28.78 | 2024 | |
| Pfizer INC. | $28.28 | 2023 | |
| Advanced Respiratory, INC | $25.97 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $23.92 | 2019 | |
| Axsome Therapeutics, INC. | $20.93 | 2024 | Sunosi |
| Resmed Corp | $18.21 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $16.97 | 2024 | Arcalyst |
| Electromed, INC. | $16.38 | 2024 | Smartvest |
| Harmony Biosciences LLC | $16.12 | 2023 | Wakix |
| Circassia INC. | $14.30 | 2019 | |
| Kaleo, INC. | $13.51 | 2022 | |
| Astellas Pharma US INC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Restifo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.